Fresenius Kabi Signs Global Licensing Deal with Polpharma

Polpharma Biologics and Fresenius Kabi sign licensing agreement

Polpharma Biologics announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialisation of PB016.

Fresenius Kabi signs global licensing deal with Polpharma

Fresenius has entered into a global licensing agreement for the commercialisation of Polpharma vedolizumab biosimilar candidate PB016.

Polpharma Biologics and Fresenius Kabi partner to develop treatment for ulcerative colitis and Crohn’s disease - Pharmafile

Polpharma Biologics has signed a global licensing agreement with Fresenius Kabi for the commercialisation of PB016, a proposed biosimilar to Entyvio (vedolizumab), for the treatment of moderate-to-severe ulcerative colitis and Crohn’s disease. The deal covers global markets excluding the Middle East and North Africa. Under the agreement, Polpharma Biologics will oversee development and manufacturing of […] The post Polpharma Biologics and Fresen…